ADMA vs BEAM: stock comparison and AI forecast
Adma Biologics, Inc. (ADMA) and Beam Therapeutics Inc. (BEAM) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ADMA Adma Biologics, Inc.
- Price
- $13.21 +56.0% · 6M
- Market Cap
- $2.96B
- P/E Ratio
- 19.7x
- Size
- mid-cap
- AI Forecast
BEAM Beam Therapeutics Inc.
- Price
- $25.87 -17.8% · 6M
- Market Cap
- $2.67B
- P/E Ratio
- 369.6x
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ADMA is 1.1 times larger than BEAM by market capitalization ($2.96B against $2.67B).
- ADMA trades at 19.7 times trailing earnings, BEAM at 369.6 times.
- Over the last six months ADMA returned +56.0% and BEAM -17.8%.
- ADMA carries 0.67 times debt per unit of equity, against 0.33 times for BEAM.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ADMA | BEAM |
|---|---|---|
| Market Cap | $2.96B | $2.67B |
| P/E Ratio | 19.72x | 369.56x |
| P/B Ratio | 6.75x | 2.80x |
| EPS | $0.67 | $0.07 |
| Book Value/Share | $1.96 | $9.22 |
| Revenue/Share | $2.32 | $1.42 |
| FCF/Share | $0.59 | $-3.86 |
Profitability & Margins
| Metric | ADMA | BEAM |
|---|---|---|
| ROE | 41.6% | – |
| ROA | 24.9% | – |
| ROIC | 37.9% | -33.1% |
| Gross Margin | 68.5% | – |
| Operating Margin | 46.5% | -267.7% |
| Net Margin | 35.1% | – |
| EBT Margin | 45.2% | -89.2% |
| Tax Rate | 22.2% | 0.0% |
Financial Health
| Metric | ADMA | BEAM |
|---|---|---|
| Current Ratio | 6.04x | 13.00x |
| Quick Ratio | 3.25x | – |
| D/E Ratio | 0.67x | 0.33x |
| Financial Leverage | 1.67x | 1.33x |
| Interest Coverage | 21.2x | -54.5x |
| Working Capital | $481M | $985M |
Cash Flow
| Metric | ADMA | BEAM |
|---|---|---|
| Operating Cash Flow | $141M | -$389M |
| Free Cash Flow | $133M | -$398M |
| Capital Spending | -$8M | -$10M |
| OCF Growth YoY | 116.7% | – |
| FCF Growth YoY | 226.4% | – |
| FCF/Sales | 25.6% | -271.6% |
| CapEx/Sales | 1.5% | 6.5% |
Operational Efficiency
| Metric | ADMA | BEAM |
|---|---|---|
| Asset Turnover | 0.71x | 0.12x |
| Receivables Turnover | 3.1x | – |
| Inventory Turnover | 0.6x | – |
| Fixed Assets Turnover | 7.8x | 1.6x |
| Days Sales Outstanding | 119 days | – |
| Days Inventory | 594 days | – |
| Payables Period | 80 days | – |
| Cash Conversion Cycle | 634 days | – |
Income Statement
| Metric | ADMA | BEAM |
|---|---|---|
| Total Revenue | $519M | $147M |
| Operating Income | $241M | -$393M |
| Net Income | $182M | – |
| R&D Expense | $14M | $409M |
| SG&A Expense | $104M | – |
| Cost of Goods Sold | $163M | – |
Dividend & Shareholder Information
| Metric | ADMA | BEAM |
|---|---|---|
| Shares Outstanding | 224M | 103M |
| Net Income Growth | -12.9% | – |
| EPS Growth | -17.3% | – |
ADMA vs BEAM: stock comparison and AI forecast
Which is bigger, ADMA or BEAM?
ADMA is 1.1 times larger than BEAM by market capitalization ($2.96B against $2.67B).
Which is cheaper on earnings, ADMA or BEAM?
ADMA trades at 19.7 times trailing earnings, BEAM at 369.6 times.
Which stock performed better over the last six months, ADMA or BEAM?
Over the last six months ADMA returned +56.0% and BEAM -17.8%.
Which one does Intratio's AI model rank higher, ADMA or BEAM?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.